Skip to main content
Erschienen in: Pediatric Cardiology 7/2017

05.07.2017 | Original Article

Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease

verfasst von: Heiner Latus, Inken Wagner, Stefan Ostermayer, Gunter Kerst, Joachim Kreuder, Dietmar Schranz, Christian Apitz

Erschienen in: Pediatric Cardiology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Persistent or recurrent pulmonary arterial hypertension (PAH) following complete surgical repair of congenital heart disease (CHD) represents one of the largest group of PAH associated with CHD (PAH-CHD) in recent registry studies and seems to have a particularly poor prognosis. However, little is known about this fourth clinical subclass of PAH-CHD, especially in children. The purpose of this study was to assess specific characteristics of invasive hemodynamics of this disease in children, including acute vasodilator testing (AVT) and pulmonary endothelial function (PEF) and to compare to patients with idiopathic PAH (IPAH), who usually present with a similar fatal clinical course. Thirty-two children with PAH were included in the study, twelve of these patients had PAH-CHD subclass 4 (mean age 8.0 ± 3.4 years) and twenty children had IPAH (mean age 8.6 ± 4.4 years). Cardiac catheterization was performed in all children, including AVT and PEF. PEF was assessed by changes in pulmonary blood flow in response to acetylcholine (Ach) using Doppler flow measurements. Pulmonary flow reserve (PFR) was calculated as the ratio of pulmonary blood flow velocity in response to Ach relative to baseline values. At baseline, the ratio of mean PA pressure to mean systemic arterial pressure (mPAP/mSAP) was comparably high in both groups (0.78 ± 0.32 vs. 0.80 ± 0.22), while the indexed pulmonary vascular resistance (PVRI) was significantly lower in the PAH-CHD group (12.6 ± 6.8 WUxm2) compared to IPAH patients (19.9 ± 10.6 WUxm2) (p = 0.04). Cardiac index was significantly higher in the PAH-CHD group (4.19 ± 1.09 l/min/m2 vs. 3.23 ± 0.76) (p = 0.017). However, AVT revealed a significantly larger maximum response (percentage of fall of PVR/SVR ratio during AVT) in the IPAH group (37 ± 22%) compared to the PAH-CHD group (13 ± 23%) (p = 0.017). PEF showed no significant difference between both patient groups (PFR 1.69 ± 0.71 vs. 1.73 ± 0.68) (p = 0.76). Our study demonstrates significant pulmonary vascular disease in children with persistent or recurrent PAH following complete surgical repair of CHD similar to IPAH patients. Although baseline measures appeared to be more favorable, pulmonary vasoreactivity was markedly impaired in PAH-CHD subclass 4, which may contribute to its negative impact on the long-term outcome of this patient group.
Literatur
2.
Zurück zum Zitat Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N (2014) Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 35(11):716–724. doi:10.1093/eurheartj/eht072 CrossRefPubMed Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N (2014) Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 35(11):716–724. doi:10.​1093/​eurheartj/​eht072 CrossRefPubMed
3.
Zurück zum Zitat Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330–340. doi:10.1056/NEJMoa1209655 CrossRefPubMed Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330–340. doi:10.​1056/​NEJMoa1209655 CrossRefPubMed
4.
Zurück zum Zitat Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369(9):809–818. doi:10.1056/NEJMoa1213917 CrossRefPubMed Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369(9):809–818. doi:10.​1056/​NEJMoa1213917 CrossRefPubMed
5.
Zurück zum Zitat Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, Investigators G (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522–2533. doi:10.1056/NEJMoa1503184 CrossRefPubMed Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, Investigators G (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522–2533. doi:10.​1056/​NEJMoa1503184 CrossRefPubMed
8.
Zurück zum Zitat Apitz C, Hansmann G, Schranz D (2016) Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii23–ii29. doi:10.1136/heartjnl-2014-307340 CrossRefPubMed Apitz C, Hansmann G, Schranz D (2016) Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii23–ii29. doi:10.​1136/​heartjnl-2014-307340 CrossRefPubMed
9.
Zurück zum Zitat Zimmermann R, Kreuder J, Michel-Behnke I, Voelkel NF, Schranz D (2006) Pulmonary flow reserve in children with idiopathic pulmonary arterial hypertension: implications for diagnosis and therapy. Eur J Med Res 11(5):208–213PubMed Zimmermann R, Kreuder J, Michel-Behnke I, Voelkel NF, Schranz D (2006) Pulmonary flow reserve in children with idiopathic pulmonary arterial hypertension: implications for diagnosis and therapy. Eur J Med Res 11(5):208–213PubMed
10.
Zurück zum Zitat Apitz C, Zimmermann R, Kreuder J, Jux C, Latus H, Pons-Kuhnemann J, Kock I, Bride P, Kreymborg KG, Michel-Behnke I, Schranz D (2012) Assessment of pulmonary endothelial function during invasive testing in children and adolescents with idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 60(2):157–164. doi:10.1016/j.jacc.2012.04.010 CrossRefPubMed Apitz C, Zimmermann R, Kreuder J, Jux C, Latus H, Pons-Kuhnemann J, Kock I, Bride P, Kreymborg KG, Michel-Behnke I, Schranz D (2012) Assessment of pulmonary endothelial function during invasive testing in children and adolescents with idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 60(2):157–164. doi:10.​1016/​j.​jacc.​2012.​04.​010 CrossRefPubMed
11.
Zurück zum Zitat Latus H, Werz A, Kock I, Rupp S, Kerst G, Kreuder J, Schranz D, Apitz C (2014) Systemic arterial endothelial function in children and young adults with idiopathic pulmonary arterial hypertension: is there a relation to pulmonary endothelium-dependent relaxation? Pediatr Cardiol 35(5):844–850. doi:10.1007/s00246-014-0864-z CrossRefPubMed Latus H, Werz A, Kock I, Rupp S, Kerst G, Kreuder J, Schranz D, Apitz C (2014) Systemic arterial endothelial function in children and young adults with idiopathic pulmonary arterial hypertension: is there a relation to pulmonary endothelium-dependent relaxation? Pediatr Cardiol 35(5):844–850. doi:10.​1007/​s00246-014-0864-z CrossRefPubMed
13.
Zurück zum Zitat Douwes JM, Humpl T, Bonnet D, Beghetti M, Ivy DD, Berger RM, Investigators T (2016) Acute vasodilator response in pediatric pulmonary arterial hypertension: current clinical practice from the TOPP REGISTRY. J Am Coll Cardiol 67(11):1312–1323. doi:10.1016/j.jacc.2016.01.015 CrossRefPubMed Douwes JM, Humpl T, Bonnet D, Beghetti M, Ivy DD, Berger RM, Investigators T (2016) Acute vasodilator response in pediatric pulmonary arterial hypertension: current clinical practice from the TOPP REGISTRY. J Am Coll Cardiol 67(11):1312–1323. doi:10.​1016/​j.​jacc.​2016.​01.​015 CrossRefPubMed
14.
Zurück zum Zitat van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, Kapusta L, Strengers JL, Rammeloo L, Clur SA, Mulder BJ, Berger RM (2011) Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 124(16):1755–1764. doi:10.1161/CIRCULATIONAHA.110.969584 CrossRefPubMed van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, Kapusta L, Strengers JL, Rammeloo L, Clur SA, Mulder BJ, Berger RM (2011) Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 124(16):1755–1764. doi:10.​1161/​CIRCULATIONAHA.​110.​969584 CrossRefPubMed
15.
Zurück zum Zitat Douwes JM, van Loon RL, Hoendermis ES, Vonk-Noordegraaf A, Roofthooft MT, Talsma MD, Hillege HL, Berger RM (2011) Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J 32(24):3137–3146. doi:10.1093/eurheartj/ehr282 CrossRefPubMed Douwes JM, van Loon RL, Hoendermis ES, Vonk-Noordegraaf A, Roofthooft MT, Talsma MD, Hillege HL, Berger RM (2011) Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J 32(24):3137–3146. doi:10.​1093/​eurheartj/​ehr282 CrossRefPubMed
17.
Zurück zum Zitat Haworth SG (1984) Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood. Br Heart J 52(5):557–571CrossRefPubMedPubMedCentral Haworth SG (1984) Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood. Br Heart J 52(5):557–571CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Hallidie-Smith KA, Hollman A, Cleland WP, Bentall HH, Goodwin JF (1969) Effects of surgical closure of ventricular septal defects upon pulmonary vascular disease. Br Heart J 31(2):246–260CrossRefPubMedPubMedCentral Hallidie-Smith KA, Hollman A, Cleland WP, Bentall HH, Goodwin JF (1969) Effects of surgical closure of ventricular septal defects upon pulmonary vascular disease. Br Heart J 31(2):246–260CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hallidie-Smith KA, Wilson RS, Hart A, Zeidifard E (1977) Functional status of patients with large ventricular septal defect and pulmonary vascular disease 6 to 16 years after surgical closure of their defect in childhood. Br Heart J 39(10):1093–1101CrossRefPubMedPubMedCentral Hallidie-Smith KA, Wilson RS, Hart A, Zeidifard E (1977) Functional status of patients with large ventricular septal defect and pulmonary vascular disease 6 to 16 years after surgical closure of their defect in childhood. Br Heart J 39(10):1093–1101CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Heath D, Edwards JE (1958) The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18(4 Part 1):533–547CrossRefPubMed Heath D, Edwards JE (1958) The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18(4 Part 1):533–547CrossRefPubMed
21.
Zurück zum Zitat Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L (1984) Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 69(4):655–667CrossRefPubMed Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L (1984) Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 69(4):655–667CrossRefPubMed
22.
Zurück zum Zitat Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ (1993) Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 88(5 Pt 1):2128–2138CrossRefPubMed Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ (1993) Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 88(5 Pt 1):2128–2138CrossRefPubMed
Metadaten
Titel
Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease
verfasst von
Heiner Latus
Inken Wagner
Stefan Ostermayer
Gunter Kerst
Joachim Kreuder
Dietmar Schranz
Christian Apitz
Publikationsdatum
05.07.2017
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 7/2017
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-017-1667-9

Weitere Artikel der Ausgabe 7/2017

Pediatric Cardiology 7/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.